BRPI0507579A - molécula de ácido nucleico, vetor, célula hospedeira, processo para expressar uma proteìna de fusão cea em uma célula hospedeira recombinante, proteìna de fusão cea purificada, método de prevenção ou tratamento de cáncer, plasmìdeo de vacina, e, método de tratamento de um mamìfero sofrendo de ou predisposto a um cáncer associados com cea - Google Patents
molécula de ácido nucleico, vetor, célula hospedeira, processo para expressar uma proteìna de fusão cea em uma célula hospedeira recombinante, proteìna de fusão cea purificada, método de prevenção ou tratamento de cáncer, plasmìdeo de vacina, e, método de tratamento de um mamìfero sofrendo de ou predisposto a um cáncer associados com ceaInfo
- Publication number
- BRPI0507579A BRPI0507579A BRPI0507579-3A BRPI0507579A BRPI0507579A BR PI0507579 A BRPI0507579 A BR PI0507579A BR PI0507579 A BRPI0507579 A BR PI0507579A BR PI0507579 A BRPI0507579 A BR PI0507579A
- Authority
- BR
- Brazil
- Prior art keywords
- cea
- host cell
- fusion protein
- cea fusion
- vector
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 5
- 108020001507 fusion proteins Proteins 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 3
- 241000124008 Mammalia Species 0.000 title abstract 2
- 239000013612 plasmid Substances 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 abstract 9
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 abstract 9
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 201000009030 Carcinoma Diseases 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 230000002766 immunoenhancing effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
MOLéCULA DE áCIDO NUCLEICO, VETOR, CéLULA HOSPEDEIRA, PROCESSO PARA EXPRESSAR UMA PROTEìNA DE FUSãO CEA EM UMA CéLULA HOSPEDEIRA RECOMBINANTE, PROTEìNA DE FUSãO CEA PURIFICADA, MéTODO DE PREVENçãO OU TRATAMENTO DE CáNCER, PLASMìDEO DE VACINA, E, MéTODO DE TRATAMENTO DE UM MAMìFERO SOFRENDO DE OU PREDISPOSTO A UM CáNCER ASSOCIADO COM CEA Polinuucleotídeos codificando proteínas de fusão de antígeno carcinoembriónico (CEA) são providos, as proteínas de fusão CEA compreendendo uma proteína CEA, ou uma variante funcional da mesma, fundida em uma porção substancial de um elemento imunomelhorador. Os polinucleotídeos da presente invenção podem elicitar uma resposta imune em um mamífero, que em formas de realização preferidas, é mais forte do que a resposta imune elicitada por um CEA de tipo selvagem. O gene codificando CEA é comumente associado com o desenvolvimento de carcinomas humanos. A presente invenção provê composições e métodos para elicitar ou melhorar a imunidade do produto de proteína expressado pelo antígeno associado com tumor CEA, em que a expressão de CEA aberrante é associada com um carcinoma ou seu desenvolvimento. Esta invenção especificamente provê vetor adenoviral e construções de plasmídeo transportando os polinucleotídeos codificando as proteínas de fusão CEA e descreve seu uso em vacinas e composições farmacêuticas para evitar e tratar câncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54364904P | 2004-02-11 | 2004-02-11 | |
| US63579104P | 2004-12-14 | 2004-12-14 | |
| PCT/EP2005/001114 WO2005077977A2 (en) | 2004-02-11 | 2005-02-03 | Carcinoembryonic antigen fusions proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0507579A true BRPI0507579A (pt) | 2007-07-03 |
Family
ID=34864529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0507579-3A BRPI0507579A (pt) | 2004-02-11 | 2005-02-03 | molécula de ácido nucleico, vetor, célula hospedeira, processo para expressar uma proteìna de fusão cea em uma célula hospedeira recombinante, proteìna de fusão cea purificada, método de prevenção ou tratamento de cáncer, plasmìdeo de vacina, e, método de tratamento de um mamìfero sofrendo de ou predisposto a um cáncer associados com cea |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8188244B2 (pt) |
| EP (1) | EP1716173B8 (pt) |
| JP (1) | JP5148116B2 (pt) |
| KR (1) | KR101195400B1 (pt) |
| AT (1) | ATE555127T1 (pt) |
| AU (1) | AU2005212479B2 (pt) |
| BR (1) | BRPI0507579A (pt) |
| CA (1) | CA2555013C (pt) |
| ES (1) | ES2387850T3 (pt) |
| IL (1) | IL177277A (pt) |
| NO (1) | NO340715B1 (pt) |
| NZ (1) | NZ549048A (pt) |
| RU (1) | RU2380375C2 (pt) |
| WO (1) | WO2005077977A2 (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007042169A2 (en) | 2005-10-07 | 2007-04-19 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Matrix metalloproteinase 11 vaccine |
| ATE534661T1 (de) * | 2006-10-12 | 2011-12-15 | Angeletti P Ist Richerche Bio | Fusionsprotein aus telomerase und reverser transkriptase, dafür codierende nukleotide und anwendungen davon |
| WO2009006479A2 (en) | 2007-07-02 | 2009-01-08 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
| EP2324057B1 (en) * | 2008-08-12 | 2018-03-21 | MSD Italia S.r.l. | Minigene comprising htpa signal peptide, t-cell epitopes, e. coli ltb and furin sensitive linkers |
| EP2568044B1 (en) | 2008-09-29 | 2015-04-08 | The Trustees of The University of Pennsylvania | Tumor vascular marker-targeted vaccines |
| CN103037896B (zh) * | 2010-05-11 | 2017-06-13 | 多伦多大学理事会 | 癌胚抗原的n‑结构域及其组合物、方法和用途 |
| US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| AU2013338153B2 (en) | 2012-10-29 | 2018-06-21 | The Board Of Trustees Of The University Of Arkansas | Novel mucosal adjuvants and delivery systems |
| KR102391734B1 (ko) | 2013-03-15 | 2022-04-29 | 인3바이오 리미티드 | 자기조립형 합성 단백질 |
| US9753036B2 (en) | 2014-04-29 | 2017-09-05 | Edp Biotech Corporation | Methods and compositions for screening and detecting biomarkers |
| AU2016205215B2 (en) | 2015-01-09 | 2021-03-11 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| KR20170102002A (ko) | 2015-01-09 | 2017-09-06 | 이투빅스 코포레이션 | 에볼라 바이러스 백신접종을 위한 방법 및 조성물 |
| DE202016009167U1 (de) * | 2015-04-10 | 2023-11-30 | Preclinics Gesellschaft Für Präklinische Forschung Mbh | VHH-Konstrukte zur Umleitung einer Immunantwort |
| US11149087B2 (en) | 2015-04-20 | 2021-10-19 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| US10751398B2 (en) * | 2016-10-07 | 2020-08-25 | Loyola University Chicago | Inflammasome activators and methods of use to treat tumors |
| US11548930B2 (en) * | 2017-04-04 | 2023-01-10 | Heat Biologics, Inc. | Intratumoral vaccination |
| CN111868077A (zh) | 2018-01-17 | 2020-10-30 | 南特生物公司 | Gpi锚定抗原的增强的免疫原性 |
| US20210388383A1 (en) * | 2018-10-12 | 2021-12-16 | Children's Hospital Medical Center | Modular expression systems for gene expression and methods of using same |
| IT201900016736A1 (it) * | 2019-09-19 | 2021-03-19 | Takis S R L | Antigeni fusi alla proteina Profilin-like di Toxoplasma Gondii (PFTG) e loro uso nella vaccinazione preventiva e terapeutica. |
| WO2024112717A1 (en) * | 2022-11-21 | 2024-05-30 | Avstera Therapeutics Corp. | Mrna composition for preventing and treating cancer |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5274087A (en) * | 1986-08-13 | 1993-12-28 | Molecular Diagnostics, Inc. | cDNA coding for carcinoembryonic antigen (CEA) |
| US5122599A (en) | 1986-08-13 | 1992-06-16 | Molecular Diagnostics, Inc. | CDNAS coding for members of the carcinoembryonic antigen family |
| CA2102623C (en) * | 1991-05-06 | 2003-04-22 | Jeffrey Schlom | Recombinant virus expressing carcinoembryonic antigen and methods of use thereof |
| ATE212378T1 (de) | 1993-06-04 | 2002-02-15 | Whitehead Biomedical Inst | Stressproteine und ihre verwendung |
| US5736524A (en) * | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| AU3923000A (en) | 1999-04-16 | 2000-11-02 | Amgen, Inc. | Agp-1 fusion protein compositions and methods |
| ATE284898T1 (de) * | 1999-08-25 | 2005-01-15 | Merck & Co Inc | Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind |
| WO2001024832A2 (de) | 1999-09-27 | 2001-04-12 | Gabriele Pecher | Pharmazeutische zusammensetzung zur behandlung und prophylaxe von humanen tumoren, die das tumorantigen muzin und/oder das carcinoembryonale antigen (cea) exprimieren und ihre verwendung |
| AU1013601A (en) * | 1999-10-22 | 2001-05-08 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
| CA2799545A1 (en) * | 2000-03-07 | 2001-09-13 | Merck Sharp & Dohme Corp. | Adenovirus formulations |
| WO2001089456A2 (en) | 2000-05-19 | 2001-11-29 | The Administrators Of The Tulane Educational Fund | Hybrid lt-a/ct-b holotoxin for use as an adjuvant |
| AU2001294562B2 (en) | 2000-09-15 | 2007-05-24 | Merck & Co., Inc. | Enhanced First Generation Adenovirus Vaccines Expressing Codon Optimized HIV1-Gag, Pol, Nef and Modifications |
| DE10055545A1 (de) | 2000-11-09 | 2002-07-25 | Deutsches Krebsforsch | Für Expression in Eukaryonten optimierte HPV 16-L1 und HPV 16-L2 kodierende DNA Sequenzen |
| DE60139959D1 (de) | 2000-11-27 | 2009-10-29 | Powderject Vaccines Inc | Nukleinsäureadjuvantien |
| GB0030067D0 (en) | 2000-12-11 | 2001-01-24 | Univ Bristol | Therapeutic agent |
| US20050130886A1 (en) | 2001-05-14 | 2005-06-16 | Jan Holmgren | Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit |
| AU2003203140A1 (en) | 2002-01-17 | 2003-07-30 | Pharmexa A/S | Immunogenic carcinoembryonic antigen (cea) |
| EP1597370B1 (en) * | 2003-02-13 | 2006-06-28 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Rhesus carcino embryonic antigen, nucleotides encoding same, and uses thereof |
| WO2004092216A1 (en) | 2003-04-15 | 2004-10-28 | Trangene S.A. | Carcinoembryonic antigen (cea) lacking a signal peptide, nucleic acid encoding it and fusion of cea with a t cell epitope and their use for the treatment and/or prophylaxis of cancer |
| US20070104685A1 (en) * | 2003-05-05 | 2007-05-10 | Nicola La Monica | Synthetic gene encoding human carcinoembryonic antigen and uses thereof |
| EP1658370A1 (en) | 2003-08-22 | 2006-05-24 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Synthetic gene encoding rhesus monkey carcinoembryonic antigen and uses thereof |
-
2005
- 2005-02-03 ES ES05707188T patent/ES2387850T3/es not_active Expired - Lifetime
- 2005-02-03 AU AU2005212479A patent/AU2005212479B2/en not_active Ceased
- 2005-02-03 NZ NZ549048A patent/NZ549048A/en not_active IP Right Cessation
- 2005-02-03 BR BRPI0507579-3A patent/BRPI0507579A/pt not_active Application Discontinuation
- 2005-02-03 JP JP2006552512A patent/JP5148116B2/ja not_active Expired - Fee Related
- 2005-02-03 CA CA2555013A patent/CA2555013C/en not_active Expired - Fee Related
- 2005-02-03 EP EP05707188A patent/EP1716173B8/en not_active Expired - Lifetime
- 2005-02-03 RU RU2006132340/13A patent/RU2380375C2/ru not_active IP Right Cessation
- 2005-02-03 WO PCT/EP2005/001114 patent/WO2005077977A2/en not_active Ceased
- 2005-02-03 US US10/589,180 patent/US8188244B2/en active Active
- 2005-02-03 AT AT05707188T patent/ATE555127T1/de active
- 2005-02-03 KR KR1020067018595A patent/KR101195400B1/ko not_active Expired - Fee Related
-
2006
- 2006-08-03 IL IL177277A patent/IL177277A/en not_active IP Right Cessation
- 2006-09-08 NO NO20064044A patent/NO340715B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20064044L (no) | 2006-09-08 |
| JP2007537722A (ja) | 2007-12-27 |
| CA2555013A1 (en) | 2005-08-25 |
| KR101195400B1 (ko) | 2012-10-29 |
| RU2006132340A (ru) | 2008-03-20 |
| ATE555127T1 (de) | 2012-05-15 |
| NO340715B1 (no) | 2017-06-06 |
| KR20060129456A (ko) | 2006-12-15 |
| IL177277A0 (en) | 2006-12-10 |
| EP1716173A2 (en) | 2006-11-02 |
| AU2005212479A1 (en) | 2005-08-25 |
| US8188244B2 (en) | 2012-05-29 |
| AU2005212479B2 (en) | 2009-09-10 |
| NZ549048A (en) | 2009-04-30 |
| JP5148116B2 (ja) | 2013-02-20 |
| EP1716173B8 (en) | 2012-06-27 |
| ES2387850T3 (es) | 2012-10-02 |
| IL177277A (en) | 2014-08-31 |
| US20080311137A1 (en) | 2008-12-18 |
| WO2005077977A2 (en) | 2005-08-25 |
| RU2380375C2 (ru) | 2010-01-27 |
| CA2555013C (en) | 2013-10-15 |
| WO2005077977A3 (en) | 2005-10-06 |
| EP1716173B1 (en) | 2012-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0719865A2 (pt) | molécula de ácido nucleico, proteína de fusão purificada, vetor, célula hospedeira, processo para expressar uma proteína de fusão, e, método para tratar um paciente sofrendo de ou predisposto a um câncer | |
| EP1716173B8 (en) | Carcinoembryonic antigen fusion protein and uses thereof | |
| EA200700849A1 (ru) | Первичная/бустерная противомалярийная вакцина | |
| DE60044665D1 (de) | Her2/neu fusionsproteine | |
| WO2002012341A3 (en) | Her-2/neu fusion proteins | |
| ATE444361T1 (de) | Il-17 und il-17r homologe polypeptide und deren therapeutische verwendungen | |
| WO2007130455A3 (en) | Compositions and methods for treatment of non-hodgkins lymphoma | |
| WO2002026822A3 (en) | Pumpcn compositions and uses thereof | |
| MX2024004293A (es) | Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika. | |
| WO2005028505A3 (en) | Multiepitope polypeptides for cancer immunotherapy | |
| EP1536006A4 (en) | CANCER-ANIMALS AND THEIR USE | |
| WO2002086071A3 (en) | Cancer-testis antigens | |
| WO2004099247A3 (en) | Synthetic gene encoding human carcinoembryonic antigen and uses thereof | |
| CA2532460A1 (en) | Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof | |
| WO2001075112A3 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
| EP1197550A3 (en) | Methods and compositions for diagnosing and treating disorders involving angiogenesis | |
| Xue et al. | Construction, expression, and characterization of thymosin alpha 1 tandem repeats in Escherichia coli | |
| WO2001075114A3 (en) | Chlamydia transmembrane protein as antigen, corresponding dna fragments and uses thereof | |
| WO2004087886A3 (en) | Modified adenoviral e1a constructs and methods of use thereof | |
| EP1090995A3 (en) | Mycoplasma hyopneumoniae antigen MHP3, gene encoding it and uses thereof | |
| ATE331796T1 (de) | Rhesus-karzinoembryonales antigen, dieses codierende nukleotide und verwendungen davon | |
| WO2000026239A3 (en) | $i(chlamydia) antigens and corresponding dna fragments and uses thereof | |
| EP1191036A3 (en) | Methods and compositions for diagnosing and treating disorders involving angiogenesis | |
| WO2001014536A3 (de) | Nukleinsäuremolekül, umfassend eine für ein hämocyanin kodierende nukleinsäuresequenz und mindestens eine intronsequenz | |
| ZA200602107B (en) | Piroplasmid vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANG |
|
| B25A | Requested transfer of rights approved |
Owner name: MSD ITALIA S.R.L. (IT) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |